Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 16-week, Multicenter, Prospective, Open-label, Single-arm, Phase 4 Study to Evaluate the Effect of Soliqua™ 100/33 on the Percentage of Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Insulin-naïve Patients With Very Uncontrolled Type 2 Diabetes Mellitus

NCT05114590 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05114590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05114590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 16-week, Multicenter, Prospective, Open-label, Single-arm, Phase 4 Study to Evaluate the Effect of Soliqua™ 100/33 on the Percentage of Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Insulin-naïve Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
January 27, 2022
Completion date
April 14, 2023
Enrollment
124 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus